Drugmaker Cipla Ltd has received approval from the US Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for the generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three dosage strengths. The approval covers 100/50 mcg, 250/50 mcg and 500/50 mcg strengths. The product is therapeutically […]